|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.|
|Rapid review commissioned||07/02/2022|
|Rapid review completed||08/03/2022|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that tofacitinib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.